tiprankstipranks
Trending News
More News >
RaySearch Laboratories AB Class B (RSLBF)
OTHER OTC:RSLBF
US Market

RaySearch Laboratories AB (RSLBF) Earnings Dates, Call Summary & Reports

Compare
7 Followers

Earnings Data

Report Date
Apr 29, 2026
Before Open (Confirmed)
Period Ending
2026 (Q1)
Consensus EPS Forecast
0.15
Last Year’s EPS
0.18
Same Quarter Last Year
Based on 0 Analysts Ratings

Earnings Call Summary

Q4 2025
Earnings Call Date:Feb 12, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call presents a broadly positive operational and commercial picture: record revenues, strong organic growth, improving profitability and cash position, significant clinical milestones and substantial AI adoption/use cases. Key negatives are material currency headwinds, a book-to-bill ratio below 1 and slower-than-desired traction for RayCare (partly tied to regulatory timing). Management expects margin improvement (target at least 25% for 2026) and a RayCare ramp in coming years, and has strengthened shareholder returns with a higher dividend and a 50% payout policy.
Company Guidance
The company guided to an EBIT margin of at least 25% in 2026 and said it will publish a new 3‑year medium‑term financial target during 2026; the Board proposes a SEK 4.00/share dividend for 2025 (up from SEK 3.00) and a new dividend policy from 2026 to distribute 50% of profit after tax. For context, Q4 net sales were SEK 375m (+16%, organic +28%) and FY2025 net sales SEK 1,344m (+13%, organic +19%); Q4 operating profit was SEK 92m (24% EBIT margin; currency‑adjusted 27%) and FY operating profit SEK 292m (22% margin; adjusted to SEK 353m/26% excluding SEK 37m currency losses and SEK 23m non‑recurring costs). Recurring support revenue was SEK 139m (37%) in Q4 and SEK 524m (39%) for the year; order intake grew +8% in Q4 and +17% for the year, backlog stood at SEK 1,528m with a book‑to‑bill of 0.9, Q4 cash flow was SEK 91m and year‑end cash SEK 407m with no debt. Management also highlighted a cash‑flow focus for 2026, plans to explore share buybacks, expectations of RayCare ramp‑up (4 orders in 2025) and regulatory timing for new modules (EU online adaptive in spring; US 510(k) pending for liver ablation; chemotherapy clearance around 2027).
Record Q4 and Full-Year Net Sales
Q4 net sales SEK 375 million, +16% YoY (all-time high). Full-year 2025 net sales SEK 1.344 billion, +13% YoY; organic growth +19%.
Strong Organic Growth After Currency Adjustment
Q4 organic growth (adjusted for currency headwinds) would have been +28%. Support sales growth adjusted for currency in Q4 was +16% (reported +6%).
Improved Profitability and Cash Generation
Q4 operating profit SEK 92 million, +25% YoY, EBIT margin 24% (would have been 27% adjusted for currency losses). Full-year operating profit SEK 292 million, margin 22% (adjusted margin 26% excluding currency losses and nonrecurring items). Q4 cash flow improved to SEK 91 million; cash balance end 2025 SEK 407 million and no debt.
Growing Recurring Revenue Base
Recurring support revenue for full year SEK 524 million, representing 39% of total revenues (Q4 support revenue SEK 139 million, 37% of Q4 sales), strengthening business robustness.
Major Customer Wins and Platform Expansions
Notable orders/expansions in Q4: Greater Poland Cancer Center expanded to proton planning; University of Pennsylvania selected RayStation for proton therapy across three clinics; Universitätsklinikum Gießen und Marburg chose RayStation to replace Philips Pinnacle.
Clinical and Scientific Milestones
Royal Marsden performed first online adaptive treatment on a standard Elekta linac using RayStation; Southwest Florida Proton Center delivered first patient treatments using RayStation + RayCare with IBA Proton system; RaySearch-supported teams performed the world's first clinical proton arc treatments in 2025 (named a top-10 physics breakthrough by Physics World).
AI Adoption and Productivity Gains
Deep learning segmentation used on ~270,000 patients in 2025; deep learning planning produced ~7,000 clinical plans to date. Customer case (Iridium, Belgium) shows time savings: patient modeling -44% and plan generation -47%. AI also used to speed developer workflows.
Shareholder Returns and Policy Update
Board proposes dividend SEK 4.00 per share (up from SEK 3.00). New dividend policy from 2026 to distribute 50% of profit after tax, subject to capital needs and investments.

RaySearch Laboratories AB (RSLBF) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

RSLBF Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Apr 29, 2026
2026 (Q1)
0.15 / -
0.181
Feb 12, 2026
2025 (Q4)
0.17 / 0.22
0.19114.29% (+0.03)
Nov 07, 2025
2025 (Q3)
0.14 / 0.23
0.14458.33% (+0.08)
Aug 08, 2025
2025 (Q2)
0.12 / 0.10
0.195-49.72% (-0.10)
May 09, 2025
2025 (Q1)
0.12 / 0.18
0.11755.14% (+0.06)
Feb 21, 2025
2024 (Q4)
0.14 / 0.19
0.190.22% (+0.09)
Nov 08, 2024
2024 (Q3)
0.07 / 0.14
0.069109.52% (+0.08)
Aug 16, 2024
2024 (Q2)
0.08 / 0.20
0.035459.38% (+0.16)
May 17, 2024
2024 (Q1)
0.08 / 0.12
0.056109.80% (+0.06)
Feb 23, 2024
2023 (Q4)
0.08 / 0.10
0.045124.39% (+0.06)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

RSLBF Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Feb 12, 2026
$19.85$18.95-4.53%
Nov 07, 2025
$22.14$22.140.00%
Aug 08, 2025
$31.89$32.25+1.13%
May 09, 2025
$24.42$31.86+30.49%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does RaySearch Laboratories AB Class B (RSLBF) report earnings?
RaySearch Laboratories AB Class B (RSLBF) is schdueled to report earning on Apr 29, 2026, Before Open (Confirmed).
    What is RaySearch Laboratories AB Class B (RSLBF) earnings time?
    RaySearch Laboratories AB Class B (RSLBF) earnings time is at Apr 29, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is RSLBF EPS forecast?
          RSLBF EPS forecast for the fiscal quarter 2026 (Q1) is 0.15.